tbuckley/cabot-search huggingface dataset:
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy
Authors: Dorian Forte, María García-Fernández, Abel Sánchez-Aguilera, Vaia Stavropoulou, Claire Fielding, Daniel Martín-Pérez, Juan Antonio López, Ana S.H. Costa, Laura Tronci, Efterpi Nikitopoulou, Michael Barber, Paolo Gallipoli, Ludovica Marando, Carlos López Fernández de Castillejo, Alexandar Tzankov, Sabine Dietmann, Michele Cavo, Lucia Catani, Antonio Curti, Jesús Vázquez, Christian Frezza, Brian J. Huntly, Juerg Schwaller, Simón Méndez-Ferrer
Journal: Cell Metabolism (2020)

Like normal hematopoietic stem cells, leukemic stem cells depend on their bone marrow (BM) microenvironment for survival, but the underlying mechanisms remain largely unknown. We have studied the contribution of nestin
1567TiP A phase III trial of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3
Authors: V.J. Picozzi, T. Macarulla Mercadé, P.A. Philip, C.R. Becerra, T. Dragovich
Journal: Annals of Oncology (2020)
1229P Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC)
Authors: Y. Wang, J. Zuo, L. Feng, Z. Fan, L. Wang, X. Zhang, J. Han, X. Zhou, J. Ye, B. Li, A. Lizaso, J. Zhou
Journal: Annals of Oncology (2020)
LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
Authors: M. Joerger, Y. Metaxas, A. Schmitt, D. Koeberle, K. Zaman, D. Betticher, N. Mach, C. Renner, M.T. Mark, U. Petrausch, C.B. Caspar, C. Britschgi, C. Taverna, F. Zenger, W. Mingrone, J. Schulz, C. Kopp, S. Hayoz, A. Stathis, R. von Moos
Journal: Annals of Oncology (2020)
629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
Authors: R. de Wit, C. Wülfing, D. Castellano Gauna, G. Kramer, J-C. Eymard, C.N. Sternberg, K. Fizazi, B. Tombal, A. Bamias, J. Carles, R. Iacovelli, B. Melichar, Á. Sverrisdóttir, C. Theodore, S. Feyerabend, C. Helissey, E.M. Poole, A. Ozatilgan, C. Geffriaud-Ricouard, J. de Bono
Journal: Annals of Oncology (2020)
968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer
Authors: R. Zinner, J.M. Johnson, M. Tuluc, J.M. Curry, A. Luginbuhl, C. Fundakowski, A. Yampolsky, R.A. Goldman, C. Solomides, S. Mardekian, C. Tuckey, G. LuYao, L. Harshyne, D. Arditti-Falk, D. Poller, B. Leiby, V. Bar-Ad, R. Axelrod, A. Argiris, D.M. Cognetti
Journal: Annals of Oncology (2020)
931P Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: A phase III, randomized, double-blinded trial: J-SUPPORT 1602(TOPICS)
Authors: T. Yokota, S. Zenda, I. Ota, T. Yamazaki, T. Yamaguchi, T. Ogawa, H. Tachibana, T. Toshiyasu, A. Homma, T. Miyaji, T. Mashiko, S. Hamauchi, K. Tominaga, S. Ishii, Y. Otani, N. Orito, Y. Uchitomi
Journal: Annals of Oncology (2020)
854P A multicenter clinical registry with associated biological samples of gynecological cancer patients: Pilot study of the Spanish Ovarian Cancer Research Group (GEICO 81-T)
Authors: J.A. Lopez Guerrero, M. Mendiola, J.A. Pérez-Fidalgo, I. Romero, C. Gomez Raposo, A. Herrero, J.D. Alarcon, C. Esteban Esteban, G. Marquina Ospina, M.J. Rubio, L. Sanchez, E.M. Guerra, A. González Martín
Journal: Annals of Oncology (2020)
499P Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer
Authors: I. Baraibar Argota, C. Rubio-Pérez, G. Argiles Martinez, F.J. Ros Montañá, F. Salvà, N. Mulet Margalef, J.L. Cuadra Urteaga, D.H. Marmolejo Castaneda, N. Saoudi Gonzalez, D. Ciardiello, J. Tabernero, J. Seoane, E. Elez
Journal: Annals of Oncology (2020)
‘More Walk and Less Talk’: Changing gender bias in sports medicine
Authors: Kristian Thorborg, Laura Krohn, Thomas Bandholm, Julie Sandell Jacobsen, Michael Skovdal Rathleff, Heidi Klakk, Karen Kotila
Journal: British Journal of Sports Medicine (2020)

In the Danish Society of Sports Physical Therapy (DSSF), we were greatly inspired by the paper: ‘ We need to talk about manels: the problem of implicit gender bias in sport and exercise medicine ’ published in the British Journal of Sports Medicine in 2018.1 The paper elegantly addresses gender bias in sports medicine,2 and how lack of diversity, whether it concerns skin colour, ethnicity, socioeconomic status, gender identity etc., as pointed out by Bekker et al , ‘structurally affords certain groups rights and privileges above others’. Bekker et al , use the term ‘manel’ to describe panels at conferences or meetings consisting only of men. This paper made it clear to us, that being intentional is different from having good intentions. We took it for granted that we were part of a culture that provided equal opportunities for all genders but never openly discussed it at scientific board meetings. We were wrong—and Bekker and coauthors facilitated a much-needed self-reflection.

It IS possible to achieve gender balance in Sports Medicine. The International Federation of Sports Physical Therapy World Congress changed from …
1062P EGFR-XPAT, a novel pro-drug T-cell engager (TCEs) engineered to address on-target, off-tumour toxicity and an orthogonal approach for cancer immunotherapy in EGFR, KRAS/BRAF cancers
Authors: B. Irving, A. Nazeer, F. Cattaruzza, Z. Lange, C. Koski, M. Hammond, A. Henkensiefken, B-C. Sim, M. Derynck, V. Schellenberger
Journal: Annals of Oncology (2020)
1093P The features of the tumour microenvironment and the tumour budding identify prognostic subgroups in high-risk cutaneous squamous cell carcinoma
Authors: J. Cañueto, M. Mendiburu-Eliçade, L. Corchete-Sánchez, N. García-Sancha, R. Corchado-Cobos, Á. Santos-Briz, A. Viñolas-Cuadros, M.E. Cardeñoso-Álvarez, J. Pérez-Losada, C. Román-Curto
Journal: Annals of Oncology (2020)
1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation
Authors: I. Puzanov, K. Havenith, J. Boni, H.G. Cruz, K. Anderson, T. Kopotsha, Y. Le Bruchec, J.C. Bendell, S. Kummar, K.P. Papadopoulos, P. LoRusso, J. Wuerthner
Journal: Annals of Oncology (2020)
1675MO Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot
Authors: R. Sun, S. Achkar, S. Ammari, S. Bockel, N. Douir, G. Mevel, K. Diop, S. Corbin, F. Hubert, G. Brusadin, M. Merad, A. Laville, K. Ka, A. Bossi, S. Rivera, C. Chargari, E. Deutsch
Journal: Annals of Oncology (2020)
1529P First-line (1L) liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels
Authors: A. Dean, T. Bekaii-Saab, P.M. Boland, F. Dayyani, T. Macarulla, K. Mody, B. Belanger, F. Maxwell, Y. Moore, T. Wang, B. Zhang, Z.A. Wainberg
Journal: Annals of Oncology (2020)
1505MO Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic
Authors: D.C. Guven, F. Ceylan, I.Y. Cakir, E. Cesmeci, B. Sayinalp, B. Yesilyurt, G. Guner, H.C. Yildirim, Z. Arik, A. Turker, O. Dizdar
Journal: Annals of Oncology (2020)
1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE)
Authors: P. Jimenez Fonseca, A. La Salvia, J. Capdevila, A. Castaño, M. Benavent, V. Alonso-Orduna, T. Alonso, M. Sanchez Canovas, A. Custodio, R. Garcia Centeno, M. Llanos, G. Crespo, A. Lopez de Sa, A. Teule, L. Oliva Fernández, I. Torres, J. Gallego Plazas, C. Pericay, C. Villabona, C. López
Journal: Annals of Oncology (2020)
193P Adjuvant capecitabine-containing chemotherapy is effective in both BRCA1-like and non-BRCA1-like early-stage TNBC patients
Authors: L. de Boo, K. Jóźwiak, H. Joensuu, S. Lauttia, M. Opdam, C. van Steenis, W. Brugman, R. Kluin, P. Schouten, M. Kok, P. Nederlof, M. Hauptmann, S. Linn
Journal: Annals of Oncology (2020)
607P Prognostic value of early total, free and bound to lipoprotein fractions plasma mitotane measurements in advanced adrenocortical carcinoma at the time of mitotane initiation: A prospective study of the ENDOCAN-COMETE-cancer network
Authors: A. Naman, J. Delahousse, S. Hescot, F. Castinetti, J. Hadoux, D. Drui, P. Renoult pierre, R. Libe, L. Lamartina, M. Lombès, S. Leboulleux, A. Paci, M. Faron, E. Baudin
Journal: Annals of Oncology (2020)
LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
Authors: H.A. Yu, C.S. Baik, K. Gold, H. Hayashi, M. Johnson, M. Koczywas, H. Murakami, M. Nishio, C. Steuer, W-C. Su, J. Yang, S. Karam, Z. Qi, Y. Qiu, S. Chen, C. Yu, P.A. Jänne
Journal: Annals of Oncology (2020)
52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial
Authors: J.M. Phelip, J. Desrame, J. Edeline, E. Barbier, E. Terrebonne, P. Michel, H. Perrier, L. Dahan, V. Bourgeois, F. Khemissa Akouz, E. Soularue, V. Ly Lebrun, Y. Molin, T. Lecomte, F. Ghiringhelli, R. Coriat, S. Louafi, C. Neuzillet, S. Manfredi, D. Malka
Journal: Annals of Oncology (2020)
1077MO PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: A multicenter phase II study
Authors: J. Delyon, M. Resche-Rigon, M. Renaud, J. Le Goff, S. Dalle, V. Heidelberger, L. Da Meda, V. Allain, L. Toullec, G. Carcelain, S. Mourah, S. Caillat-Zucman, M. Battistella, C. Lebbé
Journal: Annals of Oncology (2020)
CN40 The effect of type 2 diabetes on health-related quality of life in colon cancer patients
Authors: A. Karagiozidou, K. Kazakos, I. Chatzi, E. Vlachou, D-A. Owens, A. Ouzouni, A. Chatzinikolaou, M. Lavdaniti
Journal: Annals of Oncology (2020)
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
Authors: Frank G Sandmann, Nicholas G Davies, Anna Vassall, W John Edmunds, Mark Jit, Fiona Yueqian Sun, C Julian Villabona-Arenas, Emily S Nightingale, Alicia Showering, Gwenan M Knight, Katharine Sherratt, Yang Liu, Kaja Abbas, Sebastian Funk, Akira Endo, Joel Hellewell, Alicia Rosello, Rachel Lowe, Matthew Quaife, Amy Gimma, Oliver Brady, Jack Williams, Simon R Procter, Rosalind M Eggo, Yung-Wai Desmond Chan, James D Munday, Rosanna C Barnard, Georgia R Gore-Langton, Nikos I Bosse, Naomi R Waterlow, Charlie Diamond, Timothy W Russell, Graham Medley, Stefan Flasche, Katherine E Atkins, Kiesha Prem, David Simons, Megan Auzenbergs, Damien C Tully, Christopher I Jarvis, Kevin van Zandvoort, Sam Abbott, Carl A B Pearson, Thibaut Jombart, Sophie R Meakin, Anna M Foss, Adam J Kucharski, Billy J Quilty, Hamish P Gibbs, Samuel Clifford, Petra Klepac
Journal: The Lancet Infectious Diseases (2021)
1188TiP NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913
Authors: M.C. Riesco Martínez, J. Capdevila, V. Alonso, A. Teule, E. Grande, P. Jimenez-Fonseca, M. Benavent, T. Alonso Gordoa, A. Custodio, C. Hierro Carbó, C. López, I. Sevilla García, R. García-Carbonero
Journal: Annals of Oncology (2020)
1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis
Authors: A. Garcia-Alvarez, N. Saoudi, G. Villacampa Javierre, J.D.D. Assaf Pastrana, P. Iranzo, A. Callejo, N. Pardo, S. Cedres, A. Martinez-Marti, R. Dienstmann, E. Felip, A. Navarro
Journal: Annals of Oncology (2020)
New techniques in endocytoscopy: submucosal injection heightens the visibility
Authors: Yoshiaki Kimoto, Ken Ohata, Maiko Takita, Yohei Minato, Takashi Muramoto, Yoshiyuki Kayashima, Ikuro Koba
Journal: Endoscopy (2020)

Endocytoscopy involves the use of a light contact microscope capable of magnifying endoscopic images up to × 520, allowing optical biopsy to the cellular level [1] [2].
732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study
Authors: A. Fléchon, C.M. Chevreau, D. Topart, G. Gravis, S. Oudard, J.M. Tourani, L. Geoffrois, E. Meriaux, A. Thiery-Vuillemin, P. Barthélémy, S. Ladoire, B. Laguerre, R. Bourouina, V. Perrot, B. Escudier, M. Gross-Goupil, L. Albiges
Journal: Annals of Oncology (2020)
LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
Authors: C. Borg, E. Rullier, F. Marchal, P-L. Etienne, E. Rio, E. Francois, N. Mesgouez-Nebout, V. Vendrely, X. Artignan, O. Bouche, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. de la Fouchardiere, B. Juzyna, C. Mollevi, F. Castan, T. Conroy
Journal: Annals of Oncology (2020)
1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912
Authors: E.J. Sherman, J. Harris, K.C. Bible, P. Xia, R.A. Ghossein, C.H. Chung, N. Riaz, B. Gunn, R.L. Foote, S. Yom, S.J. Wong, S. Koyfman, M.F. Dzeda, D.A. Clump, S. Khan, A. Chakravarti, K. Redmond, P. Torres-Saavedra, Q-T. Le, N. Lee
Journal: Annals of Oncology (2020)
1817MO Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC)
Authors: P. Lapidari, A. Gbenou, J. Havas, E. Martin, B. Pistilli, A-L. Martin, S. Everhard, C. Coutant, P.H. Cottu, A. Lesur, F. Lerebours, O. Tredan, L. Vanlemmens, C. Jouannaud, C. Levy, O. Rigal, M. Fournier, F. André, I. Vaz-Luis, A. Di Meglio
Journal: Annals of Oncology (2020)
DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma
Authors: Lorenzo Nevi, Sabina Di Matteo, Guido Carpino, Ilaria Grazia Zizzari, Samira Safarikia, Valeria Ambrosino, Daniele Costantini, Diletta Overi, Antonella Giancotti, Marco Monti, Daniela Bosco, Valerio De Peppo, Andrea Oddi, Agostino Maria De Rose, Fabio Melandro, Maria Consiglia Bragazzi, Jessica Faccioli, Sara Massironi, Gian Luca Grazi, Pierluigi Benedetti Panici, Paquale Bartomeo Berloco, Felice Giuliante, Vincenzo Cardinale, Pietro Invernizzi, Giuseppina Caretti, Eugenio Gaudio, Domenico Alvaro
Journal: Hepatology (2020)

Cholangiocarcinoma (CCA) is a very aggressive cancer showing the presence of high cancer stem cells (CSCs). Doublecortin-like kinase1 (DCLK1) has been demonstrated as a CSC marker in different gastroenterological solid tumors. Our aim was to evaluate in vitro the expression and the biological function of DCLK1 in intrahepatic CCA (iCCA) and perihilar CCA (pCCA).Specimens surgically resected of human CCA were enzymatically digested, submitted to immunosorting for specific CSC markers (LGR5 [leucine-rich repeat-containing G protein-coupled receptor], CD [clusters of differentiation] 90, EpCAM [epithelial cell adhesion molecule], CD133, and CD13), and primary cell cultures were prepared. DCLK1 expression was analyzed in CCA cell cultures by real-time quantitative PCR, western blot, and immunofluorescence. Functional studies have been performed by evaluating the effects of selective DCLK1 inhibitor (LRRK2-IN-1) on cell proliferation (MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay, cell population doubling time), apoptosis, and colony formation capacity. DCLK1 was investigated in situ by immunohistochemistry and real-time quantitative PCR. DCLK1 serum concentration was analyzed by enzyme-linked immunosorbent assay. We describe DCLK1 in CCA with an increased gene and protein DCLK1 expression in pCCALGR5+ and in iCCACD133+ cells compared with unsorted cells. LRRK2-IN-1 showed an anti-proliferative effect in a dose-dependent manner. LRRK2-IN-1 markedly impaired cell proliferation, induced apoptosis, and decreased colony formation capacity and colony size in both iCCA and pCCA compared with the untreated cells. In situ analysis confirmed that DCLK1 is present only in tumors, and not in healthy tissue. Interestingly, DCLK1 was detected in the human serum samples of patients with iCCA (high), pCCA (high), HCC (low), and cirrhosis (low), but it was almost undetectable in healthy controls.DCLK1 characterizes a specific CSC subpopulation of iCCACD133+ and pCCALGR5+ , and its inhibition exerts anti-neoplastic effects in primary CCA cell cultures. Human DCLK1 serum might represent a serum biomarker for the early CCA diagnosis.
LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration
Authors: S. Banerjee, K.H.J. Lim, K.V. Kamposioras, K. Murali, C. Oing, K. Punie, M. O'Connor, B. Devnani, M. Lambertini, C. Benedikt Westphalen, P. Garrido Lopez, T.M.S. Amaral, E. Thorne, G. Morgan, J.B.A.G. Haanen, C. Hardy
Journal: Annals of Oncology (2020)
986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
Authors: A.R.R. He, K. Numata, K-H. Lee, C-H. Hsu, J. Lee, M. Morimoto, W. Verret, S.P. Hack, J. Spahn, B. Liu, B-Y. Ryoo
Journal: Annals of Oncology (2020)
247P Population-based testing for hereditary breast and ovarian cancer in a cohort of 1,346 patients from Southern Italy (Sicily): When historical background affects genetics
Authors: D. Fanale, L. Incorvaia, M. Bono, V. Calò, D. Cancelliere, A. Fiorino, A. Pivetti, N. Barraco, C. Brando, M. Castiglia, A. Perez, L.R. Corsini, G. Madonia, M.R. Ricciardi, A. Cucinella, M.C. Lisanti, C. Filorizzo, L.M. Tomasello, A. Russo, V. Bazan
Journal: Annals of Oncology (2020)
832P GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
Authors: J.A. Perez Fidalgo, A. Cortés, Y. García, M. Iglesias, U. Bohn Sarmiento, E. Calvo García, L. Manso Sánchez, A. Santaballa, A. Oaknin, A. Redondo, M.J. Rubio, A. González Martín
Journal: Annals of Oncology (2020)
1448P Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
Authors: J-S. Wang, T. Wu, Y-G. Hong, Y-Z. Guo, S-X. Luo, N. Li, Y-F. Cheng, B-S. Li
Journal: Annals of Oncology (2020)
691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status
Authors: U. De Giorgi, N. Shore, S. Sridharan, M. Gleave, B. Rosbrook, Q. Shen, J. Sugg, G.P. Haas, S.J. Freedland
Journal: Annals of Oncology (2020)
1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials
Authors: M. Ozguroglu, K. Shitara, K-W. Lee, C.S. Fuchs, H.C. Chung, M. Di Bartolomeo, J. Chao, Z.A. Wainberg, C. Caglevic, I. Kudaba, E. Van Custem, M. Garrido, J. Lee, J. Ma, Z.A. Cao, S. Shah, C-S. Shih, P. Bhagia, L. Wyrwicz, J. Tabernero
Journal: Annals of Oncology (2020)
636P A study of sustained androgen signaling dependence in metastatic castrate resistant prostate cancer (mCRPC)
Authors: M. Boukovala, N. Spetsieris, K. Karalis, I. Alafis, J.A. Weldon, M. Karlou, S-M. Tu, A. Aparicio, J.C. Araujo, P. Corn, S.K. Subudhi, A.J. Zurita-Saavedra, C. Logothetis, E. Efstathiou
Journal: Annals of Oncology (2020)
Three-dimensional bioprinting of multicell-laden scaffolds containing bone morphogenic protein-4 for promoting M2 macrophage polarization and accelerating bone defect repair in diabetes mellitus
Authors: Xin Sun, Zhenjiang Ma, Xue Zhao, Wenjie Jin, Chenyu Zhang, Jie Ma, Lei Qiang, Wenhao Wang, Qian Deng, Han Yang, Jinzhong Zhao, Qianqian Liang, Xiaojun Zhou, Tao Li, Jinwu Wang
Journal: Bioactive Materials (2020)

Critical-sized bone defect repair in patients with diabetes mellitus remains a challenge in clinical treatment because of dysfunction of macrophage polarization and the inflammatory microenvironment in the bone defect region. Three-dimensional (3D) bioprinted scaffolds loaded with live cells and bioactive factors can improve cell viability and the inflammatory microenvironment and further accelerating bone repair. Here, we used modified bioinks comprising gelatin, gelatin methacryloyl (GelMA), and 4-arm poly (ethylene glycol) acrylate (PEG) to fabricate 3D bioprinted scaffolds containing BMSCs, RAW264.7 macrophages, and BMP-4-loaded mesoporous silica nanoparticles (MSNs). Addition of MSNs effectively improved the mechanical strength of GelMA/gelatin/PEG scaffolds. Moreover, MSNs sustainably released BMP-4 for long-term effectiveness. In 3D bioprinted scaffolds, BMP-4 promoted the polarization of RAW264.7 to M2 macrophages, which secrete anti-inflammatory factors and thereby reduce the levels of pro-inflammatory factors. BMP-4 released from MSNs and BMP-2 secreted from M2 macrophages collectively stimulated the osteogenic differentiation of BMSCs in the 3D bioprinted scaffolds. Furthermore, in calvarial critical-size defect models of diabetic rats, 3D bioprinted scaffolds loaded with MSNs/BMP-4 induced M2 macrophage polarization and improved the inflammatory microenvironment. And 3D bioprinted scaffolds with MSNs/BMP-4, BMSCs, and RAW264.7 cells significantly accelerated bone repair. In conclusion, our results indicated that implanting 3D bioprinted scaffolds containing MSNs/BMP-4, BMSCs, and RAW264.7 cells in bone defects may be an effective method for improving diabetic bone repair, owing to the direct effects of BMP-4 on promoting osteogenesis of BMSCs and regulating M2 type macrophage polarization to improve the inflammatory microenvironment and secrete BMP-2.
652P Comparison of current systemic combination therapies for metastatic hormone-sensitive prostate cancer and selection of candidates for optimal treatment: A systematic review and Bayesian network meta-analysis
Authors: J. Chen, Y. Ni, G. Sun, X. Zhang, J. Zhao, S. Zhu, Z. Wang, H. Zhang, X. Zhu, P. Shen, H. Zeng
Journal: Annals of Oncology (2020)